<DOC>
	<DOCNO>NCT02171195</DOCNO>
	<brief_summary>The purpose study determine safety tolerability single rise oral dos BIA 2-093 ( propose dose 20mg , 50mg , 100mg , 200mg , 400mg , 600mg , 900mg 1200mg ) group 8 healthy male adult volunteer .</brief_summary>
	<brief_title>A Single Centre , Phase I , Double-blind , Randomised , Placebo-controlled Study Investigate Safety , Tolerability , Pharmacokinetic Profile Effects EEG Single Rising Oral Doses BIA 2-093</brief_title>
	<detailed_description>Single centre , Phase I , double-blind , randomise , placebo-controlled study investigate single rise oral dos BIA 2-093 1200 mg sequential group eight healthy male adult subject . Within group eight subject two subject randomise receive placebo remain six subject randomise receive BIA 2-093 . No subject member one treatment group . Doses 20mg , 50mg , 100mg , 200mg , 400mg , 600mg , 900mg 1200mg investigated ascend order . Progression dose occur previous dose level deem safe well tolerated investigator sponsor .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Adult male age 1835 year , body mass index ( BMI ) 1928 kg/m2 . Subjects healthy determine prestudy medical history , physical examination , 12lead ECG EEG . Subjects clinical laboratory test acceptable investigator . Subjects negative HbsAg , antiHCV HIV I II test screen . Subjects negative drug abuse alcohol test screen admission . Subjects nonsmoker smoke less 10 cigarette ( equivalent ) per day . Subjects able willing give write informed consent . Subjects conform inclusion criterion . Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , connective tissue diseases disorder . Subjects clinically relevant surgical history . Subjects clinically relevant family history . Subjects history relevant atopy . Subjects history relevant drug hypersensitivity ( carbamazepine relate compound ) Subjects history alcoholism . Subjects history drug abuse . Subjects consume 28 unit alcohol week . Subjects significant infection know inflammatory process screen and/or admission Subjects acute gastrointestinal symptom time screen and/or admission ( e.g . nausea , vomit , diarrhoea , heartburn ) . Subjects acute infection influenza time screen and/or admission . Subjects use prescription drug within 4 week dose . Subjects use counter medication , exclude routine vitamin include mega dose vitamin therapy , within one week dosing . Subjects use investigational drug and/or participate clinical trial within 3 month admission study . Subjects donate and/or receive blood blood product within 3 month prior screen . Subjects vegetarian , vegan and/or medical dietary restriction . Subjects could communicate reliably investigator . Subjects unlikely cooperate requirement study . Subjects unwilling unable give write informed consent .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Eslicarbazepine acetate</keyword>
	<keyword>BIA 2-093</keyword>
	<keyword>Epilepsy</keyword>
</DOC>